Biofarm S.A.

BVB:BIO Stock Report

Market Cap: RON 1.3b

Biofarm Past Earnings Performance

Past criteria checks 3/6

Biofarm has been growing earnings at an average annual rate of 7.9%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 5.2% per year. Biofarm's return on equity is 19.8%, and it has net margins of 26.6%.

Key information

7.92%

Earnings growth rate

7.92%

EPS growth rate

Pharmaceuticals Industry Growth12.39%
Revenue growth rate5.16%
Return on equity19.80%
Net Margin26.59%
Next Earnings Update13 Nov 2026

Recent past performance updates

Analysis Article • Apr 01

Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Despite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...

Recent updates

Analysis Article • Apr 01

Biofarm (BVB:BIO) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Despite posting some strong earnings, the market for Biofarm S.A.'s ( BVB:BIO ) stock hasn't moved much. We did some...
Analysis Article • Mar 18

Is Biofarm S.A.'s (BVB:BIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Biofarm's (BVB:BIO) stock is up by a considerable 40% over the past three months. Given that the market rewards strong...
Analysis Article • Feb 18

Is There More To The Story Than Biofarm's (BVB:BIO) Earnings Growth?

Many investors consider it preferable to invest in profitable companies over unprofitable ones, because profitability...
Analysis Article • Jan 23

Shareholders Of Biofarm (BVB:BIO) Must Be Happy With Their 140% Total Return

When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...
Analysis Article • Dec 25

A Look At The Intrinsic Value Of Biofarm S.A. (BVB:BIO)

Today we will run through one way of estimating the intrinsic value of Biofarm S.A. ( BVB:BIO ) by taking the expected...
Analysis Article • Dec 03

Could The Biofarm S.A. (BVB:BIO) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Biofarm S.A. ( BVB:BIO ) have power over the company. Institutions often own shares in...

Revenue & Expenses Breakdown

How Biofarm makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BVB:BIO Revenue, expenses and earnings (RON Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 26294781320
31 Mar 263171011210
31 Dec 253191011200
30 Sep 25319881180
30 Jun 25309811170
31 Mar 25310861250
31 Dec 24287741090
30 Sep 24282801040
30 Jun 24259691030
31 Mar 2425666940
31 Dec 23280771100
30 Sep 23297751170
30 Jun 23301771160
31 Mar 23297761120
31 Dec 22277711060
30 Sep 22269711010
30 Jun 2226068980
31 Mar 2225365940
31 Dec 2123960900
30 Sep 2124164900
30 Jun 2123161860
31 Mar 2121558800
31 Dec 2021654820
30 Sep 2021456800
30 Jun 2020552810
31 Mar 2021153880
31 Dec 1919551750
30 Sep 1918942880
30 Jun 1919544640
31 Mar 1918943650
31 Dec 1818438640
30 Sep 1817943610
30 Jun 1817138640
31 Mar 1817639590
31 Dec 1717036580
30 Sep 1716735530
30 Jun 1716535550
31 Mar 1715532520
31 Dec 1615229520
30 Sep 1614929450
30 Jun 1614827580
31 Mar 1613820440
31 Dec 1514927440
30 Sep 1514727480

Quality Earnings: BIO has high quality earnings.

Growing Profit Margin: BIO's current net profit margins (26.6%) are higher than last year (26.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BIO's earnings have grown by 7.9% per year over the past 5 years.

Accelerating Growth: BIO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: BIO had negative earnings growth (-3.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12%).

Return on Equity

High ROE: BIO's Return on Equity (19.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/15 10:44
End of Day Share Price 2026/08/24 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biofarm S.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Vladimira UrbankovaErste Group Bank AG
Raluca FloreaErste Group Bank AG